AIMS/HYPOTHESIS: The aim of this study was to determine whether the mean size of fat cells in either visceral or subcutaneous adipose tissue has an impact on the metabolic and inflammatory profiles in morbid obesity. METHODS: In 80 morbidly obese women, mean visceral (omental) and subcutaneous fat cell sizes were related to in vivo markers of inflammation, glucose metabolism and lipid metabolism. RESULTS: Visceral, but not subcutaneous, adipocyte size was significantly associated with plasma apolipoprotein B, total cholesterol, LDL-cholesterol and triacylglycerols (p ranging from 0.002 to 0.015, partial r ranging from 0.3 to 0.4). Subcutaneous, but not visceral, adipocyte size was significantly associated with plasma insulin and glucose, insulin-induced glucose disposal and insulin sensitivity (p ranging from 0.002 to 0.005, partial r ranging from -0.34 to 0.35). The associations were independent of age, BMI, body fat mass or body fat distribution. Adipose tissue hyperplasia (i.e. many small adipocytes) in both regions was significantly associated with better glucose, insulin and lipid profiles compared with adipose hypertrophy (i.e. few large adipocytes) in any or both regions (p ranging from <0.0001 to 0.04). Circulating inflammatory markers were not associated with fat cell size or corresponding gene expression in the fat cell regions examined. CONCLUSIONS/ INTERPRETATION: In morbidly obese women region-specific variations in mean adipocyte size are associated with metabolic complications but not systemic or adipose inflammation. Large fat cells in the visceral region are linked to dyslipidaemia, whereas large subcutaneous adipocytes are important for glucose and insulin abnormalities. Hyperplasia (many small adipocytes) in both adipose regions may be protective against lipid as well as glucose/insulin abnormalities in obesity.
AIMS/HYPOTHESIS: The aim of this study was to determine whether the mean size of fat cells in either visceral or subcutaneous adipose tissue has an impact on the metabolic and inflammatory profiles in morbid obesity. METHODS: In 80 morbidly obesewomen, mean visceral (omental) and subcutaneous fat cell sizes were related to in vivo markers of inflammation, glucose metabolism and lipid metabolism. RESULTS: Visceral, but not subcutaneous, adipocyte size was significantly associated with plasma apolipoprotein B, total cholesterol, LDL-cholesterol and triacylglycerols (p ranging from 0.002 to 0.015, partial r ranging from 0.3 to 0.4). Subcutaneous, but not visceral, adipocyte size was significantly associated with plasma insulin and glucose, insulin-induced glucose disposal and insulin sensitivity (p ranging from 0.002 to 0.005, partial r ranging from -0.34 to 0.35). The associations were independent of age, BMI, body fat mass or body fat distribution. Adipose tissue hyperplasia (i.e. many small adipocytes) in both regions was significantly associated with better glucose, insulin and lipid profiles compared with adipose hypertrophy (i.e. few large adipocytes) in any or both regions (p ranging from <0.0001 to 0.04). Circulating inflammatory markers were not associated with fat cell size or corresponding gene expression in the fat cell regions examined. CONCLUSIONS/ INTERPRETATION: In morbidly obesewomen region-specific variations in mean adipocyte size are associated with metabolic complications but not systemic or adipose inflammation. Large fat cells in the visceral region are linked to dyslipidaemia, whereas large subcutaneous adipocytes are important for glucose and insulin abnormalities. Hyperplasia (many small adipocytes) in both adipose regions may be protective against lipid as well as glucose/insulin abnormalities in obesity.
Authors: Birgit Gustafson; Ann Hammarstedt; Christian X Andersson; Ulf Smith Journal: Arterioscler Thromb Vasc Biol Date: 2007-09-06 Impact factor: 8.311
Authors: Kirsi A Virtanen; Peter Lönnroth; Riitta Parkkola; Pauliina Peltoniemi; Markku Asola; Tapio Viljanen; Tuula Tolvanen; Juhani Knuuti; Tapani Rönnemaa; Risto Huupponen; Pirjo Nuutila Journal: J Clin Endocrinol Metab Date: 2002-08 Impact factor: 5.958
Authors: Vanessa van Harmelen; Anna Eriksson; Gaby Aström; Kerstin Wåhlén; Erik Näslund; Fredrik Karpe; Keith Frayn; Tommy Olsson; Jonas Andersson; Mikel Rydén; Peter Arner Journal: Diabetes Date: 2007-11-19 Impact factor: 9.461
Authors: T McLaughlin; A Sherman; P Tsao; O Gonzalez; G Yee; C Lamendola; G M Reaven; S W Cushman Journal: Diabetologia Date: 2007-06-05 Impact factor: 10.122
Authors: Erik Arner; Pål O Westermark; Kirsty L Spalding; Tom Britton; Mikael Rydén; Jonas Frisén; Samuel Bernard; Peter Arner Journal: Diabetes Date: 2009-10-21 Impact factor: 9.461
Authors: James E N Minchin; Ingrid Dahlman; Christopher J Harvey; Niklas Mejhert; Manvendra K Singh; Jonathan A Epstein; Peter Arner; Jesús Torres-Vázquez; John F Rawls Journal: Proc Natl Acad Sci U S A Date: 2015-03-23 Impact factor: 11.205
Authors: D Eriksson-Hogling; D P Andersson; J Bäckdahl; J Hoffstedt; S Rössner; A Thorell; E Arner; P Arner; M Rydén Journal: Int J Obes (Lond) Date: 2015-02-10 Impact factor: 5.095
Authors: Hui Gao; Niklas Mejhert; Jackie A Fretz; Erik Arner; Silvia Lorente-Cebrián; Anna Ehrlund; Karin Dahlman-Wright; Xiaowei Gong; Staffan Strömblad; Iyadh Douagi; Jurga Laurencikiene; Ingrid Dahlman; Carsten O Daub; Mikael Rydén; Mark C Horowitz; Peter Arner Journal: Cell Metab Date: 2014-05-22 Impact factor: 27.287
Authors: Tamara Tchkonia; Thomas Thomou; Yi Zhu; Iordanes Karagiannides; Charalabos Pothoulakis; Michael D Jensen; James L Kirkland Journal: Cell Metab Date: 2013-04-11 Impact factor: 27.287